The Restless Legs Syndrome Treatment Market will grow at highest pace

Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a medical condition characterized by an irresistible urge to move one’s body to stop uncomfortable or odd sensations. The exact cause of RLS remains unknown but it’s often associated with conditions like iron deficiency, kidney failure, and pregnancy. Treatment options for RLS include dopamine agonists, opioids, benzodiazepines, anticonvulsants, and lifestyle modifications.

The restless legs syndrome treatment market is estimated to be valued at USD 2.5 Bn in 2024 and is expected to reach USD 2.64 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031.

Key Takeaways
The key players operating in the restless legs syndrome treatment market are GlaxoSmithKline plc, Ligand Pharmaceuticals, Axsome Therapeutics, and Jazz Pharmaceuticals plc.

The growing prevalence of Restless Legs Syndrome Treatment Market worldwide owing to increasing awareness about the condition and improved diagnosis is a major factor driving market growth. According to the Restless Legs Syndrome Foundation, around 12-15% of the adult population suffers from RLS, with women more commonly affected than men.

Technological advancements in RLS diagnosis and treatment such as the development of new classes of dopamine agonists and other novel drug therapies are further fueling market expansion. Pipeline drugs under clinical trials for RLS offer promising treatment options with fewer side effects.

Market Trends
Increasing generic competition with patent expiries of branded RLS drugs is bringing down treatment costs and improving accessibility. However, it is also intensifying price wars among manufacturers.

Adoption of combination drug therapies involving dopamine agonists, anticonvulsants, opioids, etc. for better symptom management is emerging as a key trend. Combination therapies allow lower drug doses and reduced side effects.

Market Opportunities
Growing focus on developing pediatric RLS treatments presents significant opportunities as the disease also affects around 10-15% of children. Currently, treatment options for children are very limited.

Significant scope remains for market players to promote awareness and diagnostics in undiagnosed populations, especially in developing regions. This can help identify more RLS patients eligible for treatment.

Impact of COVID-19 on Restless Legs Syndrome Treatment Market Growth

The outbreak of COVID-19 has significantly impacted the Restless Legs Syndrome Treatment market. During the initial lockdown phases globally, patients visited hospitals only for emergencies which led to postponed appointments and treatment plans for RLS. This negatively impacted the sales of drugs and other therapeutics in 2020. However, with the relaxation of lockdowns and operation of healthcare facilities with strict protocols, the market is recovering gradually. Teleconsultations and online treatment options emerged as alternatives for patients to continue their treatment from home during lockdowns.

Pharmaceutical companies are focusing on developing new oral and injectable drug formulations for home-based treatment and administration. This shift can help the market sustain its growth post-pandemic as home healthcare sees increased adoption. Further clinical research on the virus’s impact and medication effectiveness for RLS patients may lead to optimized treatment approaches. Adherence to safety guidelines is critical for healthcare workers, patients and their families to minimize virus spread during in-person treatment delivery.

The value concentration of the Restless Legs Syndrome Treatment market is highest in North America.

North America accounts for the maximum share of the global Restless Legs Syndrome Treatment market in terms of value. This is primarily attributed to high diagnosis and treatment rates in countries like the United States. Increased awareness about RLS symptoms and management options among patients and physicians supplements market growth. High healthcare spending and availability of advanced therapeutics also contribute to North America’s large market share.

The Asia Pacific region is projected to witness the fastest growth in the Restless Legs Syndrome Treatment market during the forecast period.

The Asia Pacific region, led by emerging economies like China and India, is expected to record the highest CAGR for the Restless Legs Syndrome Treatment market over 2022-2028. Rapidly expanding healthcare sector, large patient pool, growing medical tourism, and rising disposable incomes in the region are major growth drivers. Greater efforts by public and private organizations to educate people about neurological disorders and improving access to diagnosis and treatments will boost the APAC market in the coming years.

Get more insights on – Restless Legs Syndrome Treatment Market

Get this Report in Japanese Language:  レストレスレッグス症候群治療市場

Get this Report in Korean Language: 하지불안증후군 치료 시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)